Vtv Therapeutics Inc. (VTVT) — SEC Filings
Vtv Therapeutics Inc. (VTVT) — 32 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 19 8-K, 6 10-Q, 2 DEF 14A.
View Vtv Therapeutics Inc. on SEC EDGAR
Overview
Vtv Therapeutics Inc. (VTVT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: vTv Therapeutics Inc. reported a significant increase in its net loss, reaching $8.7 million for the three months ended September 30, 2025, compared to $4.8 million for the same period in 2024. The net loss for the nine months ended September 30, 2025, also widened to $19.8 million from $14.8 millio
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 28 neutral, 2 mixed. The dominant filing sentiment for Vtv Therapeutics Inc. is neutral.
Filing Type Overview
Vtv Therapeutics Inc. (VTVT) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 SC 13D/A, 1 SC 13D with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of VTVT's 29 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$8.7M |
| EPS | N/A |
| Debt-to-Equity | 0.41 |
| Cash Position | $98.5M |
| Operating Margin | N/A |
| Total Assets | $99.5M |
| Total Debt | $0.33M |
Key Executives
- Sekhri
- Nelson
- Prasad
- Dr. Stephen L. Hoffman
- Dr. Michael L. Smith
- Felix J. Baker
- Julian C. Baker
- Alexandra A. Toohey
Industry Context
vTv Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on drug development. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding for research and commercialization.
Top Tags
financials (5) · corporate-governance (5) · 10-Q (4) · disclosure (3) · 8-K (3) · executive-compensation (3) · leadership-change (3) · sec-filing (3) · vTv Therapeutics (3) · Type 1 Diabetes (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 25, 2024):
- Sekhri — Member
- Nelson — Member
- Prasad — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $98.5M | Increased from $36.7M at Dec 31, 2024, due to private placement. |
| Net Loss (Q3 2025) | $8.7M | Widened from $4.8M in Q3 2024, indicating increased operational costs. |
| Net Loss (9M 2025) | $19.8M | Increased from $14.8M in 9M 2024, reflecting higher R&D spend. |
| R&D Expenses (Q3 2025) | $7.0M | Increased from $3.2M in Q3 2024, showing accelerated drug development. |
| Private Placement Gross Proceeds | $80.0M | Significant capital infusion in August 2025, improving liquidity. |
| Accumulated Deficit | $319.6M | As of September 30, 2025, highlighting historical unprofitability. |
| Class A Common Stock Shares Outstanding | 3,938,018 | As of September 30, 2025, increased from 2,612,257 at Dec 31, 2024, due to equity issuance. |
| SEC File Number | 001-37524 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 47-3916571 | Company's tax identification number. |
| Revenue | $0 | No revenue reported for Q2 2025 or H1 2025, consistent with prior periods. |
| Net Loss (Q2 2025) | -$2.5M | Improved from -$4.0M in Q2 2024, a 37.5% reduction. |
| Net Loss (H1 2025) | -$5.0M | Improved from -$8.0M in H1 2024, a 37.5% reduction. |
| R&D Expenses (Q2 2025) | $1.5M | Decreased by 50% from $3.0M in Q2 2024. |
| R&D Expenses (H1 2025) | $3.0M | Decreased by 50% from $6.0M in H1 2024. |
| G&A Expenses (Q2 2025) | $1.0M | Stable compared to Q2 2024. |
Frequently Asked Questions
What are the latest SEC filings for Vtv Therapeutics Inc. (VTVT)?
Vtv Therapeutics Inc. has 32 recent SEC filings from Feb 2024 to Dec 2025, including 19 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VTVT filings?
Across 32 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 28 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Vtv Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vtv Therapeutics Inc. (VTVT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vtv Therapeutics Inc.?
Key financial highlights from Vtv Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VTVT?
The investment thesis for VTVT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vtv Therapeutics Inc.?
Key executives identified across Vtv Therapeutics Inc.'s filings include Sekhri, Nelson, Prasad, Dr. Stephen L. Hoffman, Dr. Michael L. Smith and 3 others.
What are the main risk factors for Vtv Therapeutics Inc. stock?
Of VTVT's 29 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Vtv Therapeutics Inc.?
Forward guidance and predictions for Vtv Therapeutics Inc. are extracted from SEC filings as they are enriched.